bone marrow stromal cell antigen 1Genealiases: CD157 · cADPR2
Q-omics provides the consensus-scored BST1 profile across patient tissues and cancer cell-line models. BST1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BST1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, BST1 protein abundance shows 21,996 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KICH, and LSCC as cancer lineages where BST1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BST1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BST1 survival associations across molecular data types. BST1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BST1 RNA expression–survival associations across cancer types. High BST1 expression shows unfavorable associations in UVM, LGG and STAD, but favorable associations in KIRC, UCS and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BST1 RNA expression.
This table summarizes BST1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BST1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BST1 shows lower tumor expression in KICH, COAD, LUAD, THCA and LUSC and higher tumor expression in KIRC. The KICH box plot shows higher BST1 RNA expression in normal versus tumor tissue (log2 FC = −2.577, t-test p < 0.001).
This table shows molecular features associated with BST1 in patient tissues and cancer cell lines. In patient samples, BST1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BST1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
